Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Kymera Therapeutics Inc (KYMR)

Kymera Therapeutics Inc (KYMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,151,753
  • Shares Outstanding, K 61,112
  • Annual Sales, $ 78,590 K
  • Annual Income, $ -146,960 K
  • 60-Month Beta 2.27
  • Price/Sales 27.77
  • Price/Cash Flow N/A
  • Price/Book 4.83
Trade KYMR with:

Options Overview Details

View History
  • Implied Volatility 81.79% ( +1.89%)
  • Historical Volatility 48.47%
  • IV Percentile 63%
  • IV Rank 33.50%
  • IV High 169.84% on 10/20/23
  • IV Low 37.42% on 07/21/23
  • Put/Call Vol Ratio 8.67
  • Today's Volume 58
  • Volume Avg (30-Day) 40
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 2,233
  • Open Int (30-Day) 1,691

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.73
  • Number of Estimates 11
  • High Estimate -0.57
  • Low Estimate -0.87
  • Prior Year -0.70
  • Growth Rate Est. (year over year) -4.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.75 +1.83%
on 04/25/24
40.62 -17.90%
on 03/28/24
-6.15 (-15.57%)
since 03/25/24
3-Month
29.75 +12.10%
on 01/29/24
45.31 -26.40%
on 02/27/24
+1.51 (+4.74%)
since 01/25/24
52-Week
9.60 +247.40%
on 11/02/23
45.31 -26.40%
on 02/27/24
+0.40 (+1.21%)
since 04/25/23

Most Recent Stories

More News
Why Shares of Kymera Therapeutics Jumped on Tuesday

The company had a big bounce after hitting a 52-week low the day before.

SNY : 49.36 (+5.90%)
KYMR : 33.35 (-5.28%)
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Misses Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -1.45% and 30.28%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

KYMR : 33.35 (-5.28%)
BFRI : 1.6900 (+1.81%)
Join These Motley Fool Investors for "The Market Cap Game Show"

Multiplying the number of shares by the share price is just step one.

ASML : 902.51 (+1.14%)
AMZN : 173.67 (-1.65%)
MELI : 1,363.83 (-0.45%)
ETSY : 67.20 (+0.49%)
PYPL : 64.10 (-1.14%)
CELH : 71.64 (-0.50%)
KYMR : 33.35 (-5.28%)
MA : 462.11 (-0.08%)
BOC : 16.12 (+4.34%)
PCOR : 69.82 (-1.81%)
WMT : 60.21 (+0.57%)
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -5.26% and 37.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

KYMR : 33.35 (-5.28%)
ABUS : 2.72 (-1.09%)
X-Chem and Kymera Expand Existing Partnership

X-Chem , the leading provider of innovative solutions in early-stage drug discovery, today announced the expansion of its collaboration with Kymera Therapeutics, Inc. (NASDAQ: KYMR). With the expanded...

KYMR : 33.35 (-5.28%)
Revance Therapeutics, Inc. (RVNC) Soars 8.6%: Is Further Upside Left in the Stock?

Revance Therapeutics, Inc. (RVNC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the...

RVNC : 3.29 (-7.84%)
KYMR : 33.35 (-5.28%)
All You Need to Know About Kymera Therapeutics, Inc. (KYMR) Rating Upgrade to Buy

Kymera Therapeutics, Inc. (KYMR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

KYMR : 33.35 (-5.28%)
Kymera (KYMR) Up on Positive Data From Phase I Study on KT-474

Kymera (KYMR) posts positive data from a phase I study on KT-474 for treating patients with hidradenitis suppurativa and atopic dermatitis. Sanofi to advance KT-474 in phase II study.

SNY : 49.36 (+5.90%)
AGLE : 12.01 (+8.79%)
ASLN : 0.4480 (-4.68%)
KYMR : 33.35 (-5.28%)
Delta, Kymera rise; Charter, ABM Industries fall

Stocks that traded heavily or had substantial price changes Wednesday: Delta, Kymera rise; Charter, ABM Industries fall

ABM : 44.33 (-0.45%)
VSAT : 15.33 (-4.90%)
DAL : 49.88 (+4.05%)
CHTR : 259.10 (-2.12%)
MSFT : 399.04 (-2.45%)
KYMR : 33.35 (-5.28%)
LII : 475.50 (+1.64%)
These Biotech Stocks Are the Nasdaq's Big Wednesday Winners

Business wins are shining the spotlight on these two companies.

COMP : 3.22 (-3.30%)
$NASX : 15,611.76 (-0.64%)
KYMR : 33.35 (-5.28%)
RNA : 23.83 (-5.02%)
SNY : 49.36 (+5.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States.

See More

Key Turning Points

3rd Resistance Point 35.72
2nd Resistance Point 35.00
1st Resistance Point 34.18
Last Price 33.35
1st Support Level 32.64
2nd Support Level 31.92
3rd Support Level 31.10

See More

52-Week High 45.31
Last Price 33.35
Fibonacci 61.8% 31.67
Fibonacci 50% 27.46
Fibonacci 38.2% 23.24
52-Week Low 9.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar